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Autism spectrum disorder (ASD) is a common comorbid condition in people with fragile
X syndrome (FXS). It has been assumed that ASD symptoms reflect the same underlying
psychological and neurobiological impairments in both FXS and non-syndromic ASD, which
has led to the claim that targeted pharmaceutical treatments that are efficacious for core
symptoms of FXS are likely to be beneficial for non-syndromic ASD as well. In contrast, we
present evidence from a variety of sources suggesting that there are important differences
in ASD symptoms, behavioral and psychiatric correlates, and developmental trajectories
between individuals with comorbid FXS and ASD and those with non-syndromic ASD. We
also present evidence suggesting that social impairments may not distinguish individuals
with FXS with and without ASD. Finally, we present data that demonstrate that the
neurobiological substrates of the behavioral impairments, including those reflecting core
ASD symptoms, are different in FXS and non-syndromic ASD. Together, these data suggest
that there are clinically important differences between FXS and non-syndromic ASD
that are masked by reliance on the categorical diagnosis of ASD. We argue for use of
a symptom-based approach in future research, including studies designed to evaluate
treatment efficacy.
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INTRODUCTION
Autism spectrum disorder (ASD) is a common comorbid condi-
tion in people with fragile X syndrome (FXS). The prevalence of
ASD in FXS has been estimated at 50%, although there is consid-
erable variability across studies (Demark et al., 2003; Kaufmann et
al., 2004; Harris et al., 2005; Budimirovic and Kaufmann, 2011).
This high rate of co-occurrence has led many researchers to sug-
gest that FXS, being an etiologically “simpler” (i.e., a single-gene)
disorder, will provide insights into the etiology of non-syndromic
ASD (Belmonte and Bourgeron, 2006). Arguably, these insights
have yet to materialize. In part, this reflects the fact that although
the comorbidity of FXS and ASD was first documented more
than 30 years ago (Brown et al., 1982), there is still much that we
do not understand about the comorbidity. Most importantly, we
contend that it is not clear that the ASD diagnosis in FXS reflects
the same underlying psychological (and thus, neurobiological)
impairments as in non-syndromic ASD. In other words, we lack
a definitive answer to the question, “Is ASD in FXS ‘true’ ASD?”
and the current evidence is pointing to the possibility of a negative
answer. Answering this question is critically important, especially
at this time, because of recent claims that targeted pharmaceutical
treatments found to be efficacious for core symptoms of FXS are
likely to be beneficial for individuals with non-syndromic ASD
as well (Berry-Kravis et al., 2012; Gurkan and Hagerman, 2012;
Hagerman et al., 2012). To the extent that an ASD diagnosis
reflects different or even partly different underlying impairments
in FXS and non-syndromic cases, the possibility of shared treat-
ments is reduced as well. In this paper, we present evidence
suggesting that ASD in FXS and non-syndromic ASD may differ
in important ways.
In trying to understand the FXS–ASD comorbidity, we have
turned to five types of data. First, we have explored the individual
symptoms leading to the diagnosis of ASD in FXS and the non-
syndromic case; in essence, searching for evidence of similarities
and differences in the symptom profile “earning” affected indi-
viduals the diagnosis. Second, we have examined behaviors and
impairments that, although not part of ASD diagnostic crite-
ria, are correlated with the diagnosis or correlated with autism
symptom severity, again looking for differences and similarities
between FXS and non-syndromic ASD. Third, we have explored
the developmental trajectory of autism symptoms in FXS, com-
paring it to that in non-syndromic ASD, to discern similarities
and differences between the two conditions. Fourth, we have
sought to understand the symptoms and correlates distinguishing
individuals with FXS who receive an ASD diagnosis from those
with FXS who do not receive the diagnosis in an attempt to
understand the nature of the difference between the two groups of
individuals. Fifth, we have begun to consider the neurobiological
underpinnings of ASD symptoms in FXS and in relation to the
non-syndromic case.
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In this article, we focus largely on our own research; however,
we integrate other published literature to illustrate points of
convergence and divergence from our own data. Note, however,
that the review is not exhaustive; instead, we are selective, with
the aim being to illustrate the pitfalls of assuming the equivalence
of a categorical ASD diagnosis in FXS and the non-sndromic case
(Harris, 2011). We conclude by offering an alternative conceptu-
alization of the FXS–ASD comorbidity and of the nature of the
insights each disorder can provide with regard to understanding
the other. Useful reviews of the comorbid conditions associated
with FXS, including ASD, can be found in Belmonte and Bourg-
eron (2006), Budimirovic and Kaufmann (2011), and Kaufmann
et al. (2008).
METHODOLOGICAL CONCERN: CONFOUNDING OF
ASD AND IQ
In any examination of the comorbidity of FXS and ASD, one
must address the inherent confound of cognitive ability (e.g., IQ)
with ASD symptomatology in FXS. In FXS, individuals with a
comorbid ASD diagnosis have lower IQs, on average, than those
without the diagnosis and this characteristic is present over the
life course (Bailey et al., 2001, 2000, 2001; Rogers et al., 2001;
Kau et al., 2004; Kaufmann et al., 2004; Philofsky et al., 2004;
Lewis et al., 2006; Hernandez et al., 2009; McDuffie et al., 2010).
Quantitative metrics of autism symptom severity also are related
to IQ in individuals with FXS (e.g., Hatton et al., 2006), although
this relationship is largely accounted for by the influence of fragile
X mental retardation protein (FMRP) on both variables (Kover
et al., 2013). In non-syndromic ASD, the concurrent relationship
between IQ and autism symptoms is not linear (Charman et al.,
2011; Wang et al., 2013).
The fact that the relationship between cognitive ability and
ASD symptomatology differs for FXS and non-syndromic ASD
complicates any comparison between the two disorders because,
on average, cognitive abilities are more limited in individuals with
FXS than in individuals with non-syndromic ASD; for example,
more than 90% of males with FXS have IQs in the range of
intellectual disability (Hessl et al., 2009) compared to 16–38% of
males with non-syndromic ASD (Baio, 2012; Ryland et al., 2014).
Unless differences in cognitive ability are controlled in compar-
isons between FXS and non-syndromic ASD or between individ-
uals with FXS with and without comorbid ASD, it is impossible
to unambiguously ascribe differences in ASD symptom profiles,
correlates, or developmental trajectories to etiological group or to
cognitive ability. In the subsequent sections, the data reported are
based on comparisons controlling for cognitive differences unless
otherwise noted.
As a final point, it is worth noting that comparisons of FXS and
non-syndromic ASD that involve IQ-matched samples have the
disadvantage of truncating the IQ range for non-syndromic ASD
and thereby limit generalizability of the findings. Put differently,
largely only individuals with non-syndromic ASD and an intel-
lectual disability will be included in such matched comparisons
despite the fact that they represent less than half of cases of non-
syndromic IQ (Baio, 2012; Ryland et al., 2014). This limitation
can be overcome in part by studying individuals with the Fragile
X Mental Retardation 1 (FMR1) premutation, who can exhibit
autism symptoms while displaying average-range IQs. In the
present paper, however, we focus on individuals with the FXS
full mutation because there has been substantially more research
on the ASD comorbidity in FXS than in the premutation case.
Moreover, the prevalence of ASD is higher in individuals with
FXS than in the premutation case (Bailey et al., 2008), making the
clinical importance of the issues more acute for FXS. For reviews
of the literature on ASD and premutation carriers, see Losh et al.
(2012) and Wheeler et al. (2014).
METHODOLOGICAL CONCERN: MEASURE LIMITATIONS
The conclusions reached about ASD in FXS will be intimately
tied to the measures used to assess ASD symptoms and status.
Three cautions must be raised in this regard. First, different
measures of ASD have been used across studies, with some
measures emphasizing retrospective informant report and others
observation of current behavior. The latter measures can differ in
the standardization of the conditions of observation, from spe-
cific prompts to concatenations of impressions across naturally
occurring activities. Such variability can lead to discrepant results
across studies. Second, many of the measures available have been
created for, and normed on, non-syndromic ASD cases, leaving
their appropriateness for characterizing FXS uncertain. More
importantly, these measures may lead to a “forced” fit between the
impairments presented by the individual with FXS and the scoring
rubrics, with the result being a “loss” of clinically important
nuances in symptoms. Third, in some studies, a decision about
whether a participant “has ASD” is based on meeting specified
criteria on one or more standardized measure, whereas in other
studies clinical judgment plays a role along with meeting criteria
on standardized measures. This difference in decision making
is akin to a difference between classification and true clinical
diagnosis and can also lead to discrepant results across studies. In
the present article, we do not emphasize these issues in our study
by study review for the sake of conciseness and because our goal is
to provide an illustration of the complex and clinically important
nuances lost by a failure to move beyond a simple ASD or no ASD
categorization of individuals with FXS.
ASD SYMPTOM PROFILES IN FXS AND NON-SYNDROMIC
CASES
Perhaps the most direct approach to addressing the question of
whether ASD in FXS reflects the same underlying psychological
impairments as in non-syndromic ASD is to compare the behav-
iors that lead to the diagnosis in the two conditions. Presumably,
if ASD in FXS is “true” ASD, the symptom profiles leading to
the diagnosis should be indistinguishable in the two conditions.
In a recent study (McDuffie et al., 2014), we compared the ASD
symptom profiles of 4- to 10-year-old boys with FXS who met
criteria for ASD (n = 40) to chronological age-matched boys
with ASD for whom FXS had been ruled out (n = 39), with
the ASD diagnostic classification determined by the combined
use of the Autism Diagnostic Observation Schedule (ADOS; Lord
et al., 2007) and Autism Diagnostic Interview-Revised (ADI-R;
Rutter et al., 2003) using the procedures described by Risi et al.
(2006). Because, as noted, FXS is almost invariably associated
with below average IQ in males, the sample was restricted at the
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outset to boys whose non-verbal IQs were under 85 (i.e., one
standard deviation below the mean for the test) on the Leiter
International Performance Scale-Revised (Roid and Miller, 1997).
Symptom profiles were examined using the scores assigned for the
child’s current functioning on 28 items of the ADI-R [10 in the
Reciprocal Social Interaction (RSI) domain, 10 in the Commu-
nication (Comm) domain, and 8 in the Restricted Interests and
Stereotyped Behaviors (RBS) domain].
In general, the boys with FXS and comorbid ASD showed
less severe symptoms (i.e., lower scores) than did the boys with
nonsyndromic ASD; however, significant differences emerged
only for two items in the RSI domain (social smiling and
showing/directing attention), one item in the Comm domain
(pronominal reversal), and two items in the RBS domain (unusual
preoccupations and compulsions/rituals). Thus, despite earning
an ASD diagnosis, young boys with FXS are more socially respon-
sive, less likely to engage in an atypical communicative behavior
thought to be a “signature” of ASD (i.e., pronoun reversal), and
less apt to display some higher-order repetitive behaviors than
boys with non-syndromic ASD. Interestingly, these differences
emerged despite the fact that, as would be expected in an age-
matched comparison, the participants with FXS had lower IQs, on
average, than did the boys with non-syndromic ASD, although, as
noted, all had IQs less than 85.
In an additional analysis, McDuffie et al. (2014) selected a
subset of the participants so as to create a FXS group and a
non-syndromic ASD group (n = 21 per group) that not only
met diagnostic criteria for ASD but also were matched on the
overall severity of their ASD symptoms, using calibrated sever-
ity scores from the ADOS (Gotham et al., 2009). Even in this
analysis, different symptom profiles emerged. As a group, the
participants with FXS were significantly less impaired in terms of
social smiling. There also were group differences that approached
statistical significance in the range of facial expressions used to
communicate (RSI), offering to share (RSI), the use of conven-
tional/instrumental gestures (Comm), and unusual preoccupa-
tions (RBS), all involving less severe symptoms in participants
with FXS. At the same time, however, the participants with FXS
earned significantly higher (i.e., more impaired) scores on the
display of complex mannerisms (RBS) and marginally higher
scores on circumscribed interests (RBS). These results, perhaps
even more dramatically than those of the previously described
analysis comparing groups matched only on ASD diagnoses,
suggest that the profiles of impairments that constitute ASD
are partly different in FXS and non-syndromic ASD. Note that
despite being matched on autism symptom severity, the non-
verbal IQs of the boys with FXS were lower, although not
significantly so, than those of the boys with non-syndromic
ASD.
Matching on IQ, however, does not change the picture that
emerged from the McDuffie et al.’s (2014) study. In a study of
boys with minimal or no spoken language, Wolff et al. (2012)
compared young boys with FXS and comorbid ASD to age- and
IQ-matched boys with non-syndromic ASD on ADOS items in
the RSI domain classified as measuring either social initiation
or social response. These investigators found that the boys with
FXS were less impaired than the boys with non-syndromic ASD
in terms of social smiling, range of facial expressions used for
communication, and response to joint attention, all suggesting
less impairment in social responsiveness among those with FXS
despite having an ASD diagnosis.
Although few studies have directly compared the ASD symp-
tom profiles of individuals with FXS and comorbid ASD to those
with non-syndromic ASD, several within-groups studies of FXS
have suggested many important similarities to published findings
on non-syndromic ASD, including social withdrawal, more severe
receptive than expressive language deficits, and gaze avoidance
(Budimirovic and Kaufmann, 2011). Moreover, it is important
to note that even in the McDuffie et al.’s (2014) and Wolff et
al.’s (2012) studies, the FXS and non-syndromic ASD groups
were not significantly different on all, or even most, diagnostic
symptoms.
Taken together, the studies to date demonstrate symptom
overlap between FXS and non-syndromic ASD. At the same time,
however, it is clear that important differences between the two
groups are masked by assigning a categorical diagnosis of ASD.
These symptom differences seem to suggest different underlying
problems; for example, the social impairments in FXS may be
less reflective, on average, of social indifference or a diminished
appetite for social interaction.
BEHAVIORAL CORRELATES OF ASD IN FXS AND
NON-SYNDROMIC CASES
A second approach to addressing the question of whether ASD
in FXS reflects the same underlying psychological impairments as
in non-syndromic ASD is to examine the behavioral correlates of
the ASD diagnosis and autism symptom severity. By examining
behavioral correlates that are not part of the ASD diagnosis
itself, one can begin to learn about the factors that influence
and are influenced by ASD symptoms. To the extent that the
pattern of correlations differs for FXS and non-syndromic ASD,
the possibility of different underlying psychological impairments
in the two conditions is increased. Several recent studies we have
conducted taking this approach support the hypothesis that ASD
in FXS differs in important ways from ASD in the non-syndromic
case.
Thurman et al. (2014) used the Anxiety, Depression, and
Mood Scale (ADAMS; Esbensen et al., 2003) to examine the
co-occurrence of psychiatric symptomatology in 4- to 10-year-
old boys with FXS or non-syndromic ASD. The ADAMS is an
informant report measure standardized on a large sample of
individuals with intellectual disabilities, which in the Thurman et
al.’s (2014) study was completed by the children’s biological moth-
ers. The ADAMS yields five subscale scores: Manic/Hyperactive
Behavior; Depressed Mood; Social Avoidance; General Anxiety;
and Obsessive/Compulsive Behavior. The investigators compared
the groups using several different matching strategies involv-
ing various subgroups of the sample of 82 participants. The
comparison of interest in the present context was one made
between groups (n = 16 per group) matched on chronological
age, IQ (assessed with the Leiter), and ASD symptom severity
on the ADOS using the metric introduced by Gotham et al.
(2009).
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Three findings of interest emerged. First, boys with FXS
received higher mean scores, reflective of greater psychiatric prob-
lems, on Manic/Hyperactive Behavior and General Anxiety than
did the boys with non-syndromic ASD. Interestingly, these same
scales were higher for the boys with FXS in the analyses involving
other matching strategies, indicating their ubiquity over the full
range of the FXS phenotypes. Second, the scales of the ADAMS
were, with few exceptions, highly inter-correlated for the age-,
IQ-, and ASD symptom severity-matched boys with FXS, with
the strongest correlations involving the General Anxiety scale.
In contrast, for the matched boys with non-syndromic ASD, the
significant inter-correlations were far more sparse, with the only
significant correlation being that between Social Avoidance and
Obsessive/Compulsive Behavior. Third, the correlation between
General Anxiety and Social Avoidance was significantly stronger
in the FXS group than in the age-, IQ-, and severity-matched non-
syndromic ASD group. Other researchers also have found links
between anxiety and behaviors reflective of social avoidance in
FXS (Kaufmann et al., 2008; Budimirovic and Kaufmann, 2011).
It is interesting to note first that there were substantial differ-
ences between the FXS and non-syndromic ASD groups as regards
psychiatric findings despite their equivalence in ASD symptom
severity in the Thurman et al.’s (2014) study. Thurman et al.
(2014) argue that the preponderance of inattentive, hyperactive,
and anxious behaviors in individuals with FXS may actually
interfere with participation in, and the ability to learn from, social
interaction, with these psychiatric factors thereby playing a cumu-
lative role over time in the emergence of the social impairments
that lead to an ASD diagnosis. Presumably, other factors, not
measured in this study, are at play in the non-syndromic ASD
case. Thurman et al. (2014) also suggest that the patterns of inter-
correlations among subscales indicate that the symptoms queried
on the ADAMS may tap different underlying psychological prob-
lems in FXS and non-syndromic ASD. In that vein, they argue
that anxiety appears to be heightened and at the core of social
avoidance in FXS, but not in non-syndromic ASD. Although
anxiety is also a common comorbidity in non-syndromic ASD
(Budimirovic and Kaufmann, 2011), other researchers also have
found anxiety to be more problematic in FXS than in non-
syndromic ASD (Cordeiro et al., 2011).
Other studies also have uncovered different patterns of corre-
lations between autism symptoms and other behavioral problems
in FXS and non-syndromic ASD. For example, Klusek et al. (2013)
found that communication impairments were related to measures
of vagal tone, which are thought to reflect physiological arousal
and arousal regulation, for boys with non-syndromic ASD but not
for boys with comorbid FXS and ASD. Again, such findings raise
the possibility of different mechanisms underlying the same ASD
symptoms in the two disorders.
Of course, there also are data suggesting similar patterns of
correlation in FXS and non-syndromic ASD for some domains.
Roberts et al. (2009), for example, found that baseline cortisol
levels and change in cortisol during a stressor were correlated with
social approach behavior for individuals with FXS and comorbid
ASD as well as for individuals with non-syndromic ASD, but
not for individuals with only FXS. Nevertheless, the fact that, as
discussed in this section, there also are important differences in
the patterns of correlations among behavioral domains in FXS
and non-syndromic ASD, is consistent with the notion that at least
partly different psychological and neurobiological mechanisms
underlie the ASD diagnosis in the two conditions. Again, then,
clinically important differences are obscured by reliance solely on
the categorical diagnosis of ASD.
DEVELOPMENTAL TRAJECTORY OF ASD SYMPTOMS IN FXS
AND NON-SYNDROMIC CASES
Additional insight into the nature of the psychological impair-
ments underlying ASD in FXS and non-syndromic ASD can be
gleaned by studying the developmental course of ASD symptoms
in the two conditions. More generally, Karmiloff-Smith (2012)
has argued that similar phenotypes often belie important mecha-
nistic differences that can only be discovered through studying the
emergence of the phenotypes over the life course. In one stunning
example, Karmiloff-Smith et al. (2003) have demonstrated that in
infants with Williams syndrome numerosity skills are a relative
strength and language a relative weaknesses, whereas in adults
with Williams syndrome numerosity skills are relatively weak and
language skills relatively strong.
In this vein, McDuffie et al. (2010) used retrospective data
to track age-related changes in ASD symptoms in adolescents
with FXS. In particular, these investigators conducted an in-depth
analysis of ADI-R interviews completed by the biological mothers
of 50 children and adolescents with FXS (both males and females),
comparing the responses for those who met and did not meet
criteria for autism. Assignment to the comorbid autism and no
autism groups was determined following standard ADI-criteria
for verbal individuals (i.e., participants were classified as having
FXS + ASD if they met the designated lifetime cutoff scores for
all ADI-R domains including age of onset). Change over the life
course was examined by comparing maternal responses to the 29
ADI-R items that are queried both for current functioning and
for the lifetime, or diagnostic, algorithm, with the latter items
generally being anchored to functioning between the ages of 4 and
5 years.
Considerable change was observed in severity of autism symp-
toms from the diagnostic reference age to the current age in the
McDuffie et al. (2010) sample, which had a mean chronologi-
cal age near 13 years. In the comorbid ASD group, significant
improvement was seen on 7 of 11 items in the RSI domain
and 6 of 10 items in the Comm domain. In contrast, change
was less evident in the Restricted Interests and Repetitive Behav-
iors domain, with only two of eight items showing significant
improvement. In the case of the non-ASD participants with FXS,
there was considerably less change from the diagnostic reference
age of 4–5 years to the current ratings, which is not surprising
given the relatively low (unimpaired) ADI-R scores assigned at
the diagnostic reference age. As a result, at the current age of
assessment, there was an attenuation of the difference in ASD
symptoms between the two FXS groups with age.
Hernandez et al. (2009) also observed improvement of autism
symptoms in their prospectively followed cohort of young boys
with FXS, as well as a diminishing of differences between the
groups with and without comorbid ASD. Unlike, McDuffie et
al., however, these researchers found a worsening of autism
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symptoms in the FXS boys who did not initially meet criteria
for an ASD diagnosis. The younger ages of the Hernandez et al.’s
(2009) sample (i.e., 3–8 years) might account for the differing
results across studies.
Unfortunately, neither McDuffie et al. (2010) nor Hernandez
et al. (2009) included a non-syndromic ASD comparison group;
however, comparisons of their findings with those of other studies
focused on non-syndromic ASD are possible. In particular, like
McDuffie et al. (2010); Shattuck et al. (2007) examined differences
in ADI-R lifetime and current scores for a large group of children,
adolescents, and young adults with non-syndromic ASD. In the
Shattuck et al.’s (2007) sample, improvement with age was seen
in all three domains of ASD symptomatology, a trend observed in
several other studies as well (e.g., Piven et al., 1996; Gilchrist et al.,
2001; Seltzer et al., 2003). Interestingly, however, improvements in
the Comm domain for participants with ASD in the Shattuck et
al.’s (2007) study were more modest than McDuffie et al. observed
in their comorbid FXS and autism sample, particularly in non-
verbal communication items, thereby again raising the possibility
of different mechanisms underlying symptoms of autism in FXS
and non-syndromic ASD. At the same time, however, it is impor-
tant to recognize that there were also similarities between the two
studies in symptoms that did not change. For example, limited
friendships during adolescence characterized the non-syndromic
ASD group in the Shattuck et al.’s (2007) study as well as both the
FXS groups in the McDuffie et al. study; however, we cannot rule
out the possibility that the friendship problems of the two groups
may have different causes.
It is interesting to note that the autism symptom improvement
observed in individuals with FXS by McDuffie et al. (2010) occurs
at the same time as IQ declines reflecting a further slowing
of cognitive development relative to typically developing peers
(Kover et al., 2013). In the case of non-syndromic ASD, however,
autism symptom improvement occurs in the context of stability
in IQ (Baird, 2014; Magiati et al., 2014). Thus, these data provide
further evidence that the mechanisms underlying at least some
ASD symptoms are likely to be different in the two conditions.
Again, reliance on a categorical ASD diagnosis would obscure
those differences.
SYMPTOM PROFILES IN FXS WITH ANDWITHOUT
COMORBID ASD
Numerous studies, including several we have conducted, have
been designed to understand the symptoms and correlates distin-
guishing individuals with FXS who receive an ASD diagnosis from
those with FXS who do not receive the diagnosis (see Budimirovic
and Kaufmann, 2011 for a review). Although perhaps a more
indirect approach than those considered in previous sections,
these studies can provide insight into the essential impairment(s)
distinguishing the two FXS subgroups and whether the difference
is best explained as the result of the core impairments that define
ASD in the non-syndromic case.
In the McDuffie et al.’s (2010) study described previously,
ADI-R profiles were compared for 50 children and adolescents
with FXS (both males and females) divided into those who met
and did not meet criteria for autism. Comparisons were made
for both the lifetime, or diagnostic, items (i.e., which described
functioning largely at ages 4–5 years) and the items assessing
current functioning. Importantly, McDuffie et al. controlled for
the expected differences in IQ between the two groups, using non-
verbal IQ (determined from the Leiter International Performance
Scale) as a covariate in all comparisons.
Interestingly, a multivariate analysis of covariance did not yield
a statistically significant difference between the groups for the RSI
domain items for either the lifetime items or current age items.
In contrast, statistically significant group differences associated
with large effect sizes emerged for both the Comm domain items
and the Restricted Interests and Repetitive Behaviors items, with
the comorbid FXS–ASD group being more severely impaired.
In interpreting these findings, McDuffie et al. argued that it is
difficult to view the autism diagnosis in FXS as reflecting the same
underlying problem as in non-syndromic autism in light of the
finding that impairments in reciprocal social interaction are not
what distinguishes individuals with comorbid FXS and ASD from
their peers with FXS only, once IQ is controlled.
It should be noted that, in contrast to McDuffie et al. (2010),
Hernandez et al. (2009) found that the groups with and without
autism in their prospective longitudinal study of 3- to 8-year-
olds with FXS were most discriminated by differences in adaptive
socialization. IQ differences between the subgroups existed at two
of three assessment points and were not controlled for in the
Hernandez et al.’s (2009) study, complicating interpretation of
their findings.
Rather than examining autism symptoms per se, several studies
have focused on the correlates of the ASD diagnosis or ASD
symptom severity within FXS. In one such study, McDuffie et al.
(2012) were interested in determining the ways in which the pro-
file of language impairments in FXS differed as a function of ASD
diagnostic status and ASD symptom severity. The participants
were 34 boys between the ages of 10 and 15 years, with a mean age
near 13 years. The ADI-R and ADOS were administered, as were
measures of receptive vocabulary (Peabody Picture Vocabulary
Test—Third Edition, PPVT-3; Dunn and Dunn, 1997), receptive
syntax (Test for Reception of Grammar—Second Edition, TROG-
2; Bishop, 2003), expressive vocabulary (Expressive Vocabulary
Test, EVT; Williams, 1997), and expressive syntax (Syntax Con-
struction from the Comprehensive Assessment of Spoken Lan-
guage, CASL; Carrow-Woolfolk, 1999). The sample was quite
impaired, on average, with a mean non-verbal IQ (assessed via
the Leiter International Performance Scale) near 45.
The first set of analyses in the McDuffie et al.’s (2012)study
compared the language profiles of the 16 boys who met criteria
for autism on both the ADI-R (using the original algorithm)
and the ADOS (using the Gotham et al., 2007, revised diagnostic
algorithm) and the 8 boys who did not meet criteria on either
measure (n = 8), with ambiguous cases (i.e., those who met
diagnostic criteria on only one measure) excluded. After control-
ling for group differences in non-verbal IQ and chronological
age, no statistically significant differences emerged on any of the
language measures. The lack of group differences in language
is rather surprising in light of the especially serious receptive
language impairments often reported for individuals with non-
syndromic ASD (e.g., Kjelgaard and Tager-Flusberg, 2001; Ellis
Weismer et al., 2010; Hudry et al., 2010; Kover et al., 2013),
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especially among boys with comorbid intellectual disability
(Kover et al., 2014). It may be, however, that limited statistical
power resulting from the small sample size led to the null findings,
as the authors noted.
The second set of analyses included all 34 boys and examined
the relationship between autism symptom severity and each of the
language measures, controlling for age and non-verbal IQ. In this
analysis, autism symptom severity was a significant predictor of
both receptive vocabulary and receptive syntax, but not of either
measure of expressive language skill. The finding of significant
associations between autism symptom severity and receptive lan-
guage is in keeping with expectations derived from what is known
of non-syndromic ASD; that is, receptive language impairments
are a core feature of the disorder and may be, in part, attributed
to cumulative deficits in attending and responding to the referen-
tial cues of conversational partners (Mundy and Jarrold, 2010).
In addition, several other studies have found individuals with
comorbid FXS and autism to be especially impaired in receptive
language relative to those with FXS alone (e.g., Rogers et al.,
2001; Philofsky et al., 2004; Lewis et al., 2006; Hernandez et al.,
2009).
Other differences have been found in the language profiles
of individuals with FXS according to either autism diagnostic
status or autism symptom severity. For example, autism symptom
severity was negatively related to a measure of talkativeness in a
conversational context in a sample of 10- to 17-year-old verbal
males with FXS after controlling for non-verbal IQ (Kover et al.,
2012); that is, individuals with more severe autism symptoms
(assessed via the ADOS) were more verbally reticent, an asso-
ciation that would be consistent with the lack of motivation to
engage in social interaction that is a hallmark of non-syndromic
ASD (Chevallier et al., 2012).
Thus, as in the other types of data reviewed, the differences
between individuals with FXS who do and do not meet criteria
for ASD are not always consistent with expectations derived
from the literature on non-syndromic ASD. In other words, a
categorical ASD diagnosis in individuals with FXS masks nuances
in the symptom profile that are of clinical significance. Partic-
ularly compelling empirical data in support of this point come
from Budimirovic et al. (2006), who have shown that the ASD
diagnosis in FXS appears to reflect the combination of both (a)
social avoidance and (b) social indifference, each of which is a
continuously distributed characteristic.
NEUROBIOLOGICAL SUBSTRATES OF CORE ASD SYMPTOMS
AND BEHAVIORAL CORRELATES IN FXS AND
NON-SYNDROMIC CASES
There has been considerable research into the structural and
functional characteristics of the FXS brain, as well as into other
biomarkers of the pathology associated with the syndrome. Some
of the data generated focus on differences that map onto autism
symptoms in FXS and on differences between ASD in FXS and
non-syndromic cases. If ASD is the same disorder in FXS and
the non-syndromic case, it is reasonable to expect similar profiles
across the two disorders in terms of biomarkers of pathology.
Similarly, differences in biomarkers should correlate with ASD
status or severity within FXS after other confounding factors
are controlled. As is the case with behavioral data, evidence of
both similarities and differences between the relevant subgroups
has emerged, suggesting a deeper more nuanced picture than is
captured by a simple categorical ASD diagnosis.
BRAIN STRUCTURE AND FUNCTION
In terms of brain structure, Hoeft et al. (2011) used neuroimaging
to study brain volumes in 1- to 4-year-olds with either FXS or
non-syndromic ASD. These investigators found that both groups
differed form typical controls, but in very different ways. In
general, frontal and temporal regions thought to underlie social
information processing were larger than controls for the non-
syndromic ASD group but smaller in the FXS group. Moreover,
there were no differences in brain volume according to ASD status
with the group of participants with FXS. Similarly, Meguid et
al. (2010) found that individuals with non-syndromic ASD had
a thinner cortex in several brain regions relative to individuals
with FXS and comorbid ASD. Other studies also have found
structural differences between FXS and non-syndromic ASD,
such as greater amygdala volume in non-syndromic ASD than
in FXS, with the amygdala thought to be critical in emotional
processing and responding (Hazlett et al., 2009). At the same time,
however, there are data suggesting structural differences between
individuals with FXS with and without a comorbid ASD diagnosis
(e.g., Kaufmann et al., 2003).
In a study using functional magnetic resonance imaging
(fMRI) to examine patterns of brain activation, we (Dalton
et al., 2008) examined patterns of neural activation and con-
comitant eye gaze fixation during a task that involved in pro-
cessing emotions conveyed via other people’s facial expressions.
The participants were adolescents and adults with FXS or non-
syndromic ASD, as well as typically developing controls. The
two disordered groups each showed less activation relative to
controls of the fusiform gyrus, a region integrally involved in
face processing. Nevertheless, the participants with FXS showed
increased activation of several other brain regions relative to
both of the other groups, suggesting that emotion processing
is approached somewhat differently by individuals with FXS. At
the same time, however, autism symptom severity was correlated
with activation in the fusiform gyrus, but not the amygdala
(after controlling for IQ), in the group of participants with
FXS. Unfortunately, the same metric of autism symptom severity
was not available for the non-syndromic ASD group and thus,
no analysis of within-group variation was conducted for that
group.
FMRP LEVELS
Fragile X mental retardation protein is the protein product that is
reduced or absent in FXS. FMRP levels (measured in peripheral
lymphocytes) have generally been found to be correlated with the
severity of a wide range of behavioral symptoms in both males
and females and throughout the life course. Several studies have
examined the relationship between FMRP and autism status or
symptom severity.
In the McDuffie et al.’s (2010) and Kover et al.’s (2013) studies
already discussed, we examined the relationships among FMRP,
IQ, and autism symptoms in adolescents with FXS. Although
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FMRP levels were significantly associated with symptoms in the
domains of reciprocal social interaction, communication, and
restricted interests and repetitive behaviors, none of the correla-
tions remained significant after differences in non-verbal IQ were
controlled. In the Kover et al.’s (2013) study, which was focused
on examining the predictors of the age-related trajectory of IQ
in adolescents with FXS, autism symptom severity was found to
predict the intercept (i.e., level at the first assessment) of IQ; how-
ever, no prediction was afforded by autism symptom severity after
FMRP levels were controlled, which also suggests that the FMRP-
autism symptom severity is mediated by IQ. Other investigators
also have found no difference in FMRP levels between individuals
with FXS with and without an ASD diagnosis or other index of
autism symptomatology once IQ is controlled (Cornish et al.,
2004; Loesch et al., 2007).
In short, the FMRP findings do not generally validate at the
biological level the distinction between those with and without
comorbid ASD or between those with less and more severe ASD
symptoms. Nevertheless, it is important to acknowledge that
FMRP has been shown to be a central construct in the control
of several important neural pathways implicated in a number of
disorders, including schizophrenia (D’Antoni et al., 2014; Hamil-
ton et al., 2014; Waltes et al., 2014), and non-syndromic ASD is
likely to be included in that list as well.
SUMMARY AND CONCLUSIONS
The picture emerging thus far from our data is one in which
there are important differences in the behavioral manifestations,
behavioral correlates, and neurobiological substrates of ASD in
FXS relative to non-syndromic ASD. Moreover, these differences
suggest that the underlying psychological and neurobiological
problems may be partly different in the two conditions. In par-
ticular, we have found that:
1. Individuals with FXS who are diagnosed with ASD have less
severe impairments in several of the social and communication
symptoms that are diagnostic of ASD than do individuals with
non-syndromic ASD, and these differences have emerged in
a number of analyses and cohorts and across a variety of
matching strategies. Even a hallmark symptom, such as pro-
noun reversal, distinguishes ASD in FXS and non-syndromic
cases and is particularly interesting in light of the language
and communication challenges experienced by males with FXS
(Abbeduto et al., 2007). At the same time, however, there are
areas of greater ASD symptom severity in FXS in the domain
of restricted interests and repetitive behaviors.
2. Individuals with FXS who are diagnosed with ASD also present
with a number of comorbid problems that further distin-
guish them from individuals with non-syndromic ASD. In
particular, problems with anxiety and hyperactivity are more
severe in FXS than in comorbid ASD. Moreover, there is some
suggestive evidence that these problems may be driving the
emergence of social interaction difficulties that over the course
of development create a profile of impairments that lead to the
ASD diagnosis in individuals with FXS. Although problems
in the domains of anxiety and hyperactivity occur in ASD
(Eussen et al., 2013; van Steensel et al., 2014), they do not
appear to be causally linked to autism symptoms in the same
manner in ASD as for FXS.
3. The developmental trajectory of ASD symptoms appears to
differ between individuals with FXS and comorbid ASD and
those with non-syndromic ASD. Although symptom abate-
ment, at least during the late childhood and early adoles-
cent years, occurs in both conditions, the improvements in
communication appear more dramatic in FXS, although more
prospective longitudinal data are needed to confirm this con-
clusion. The ASD symptom improvement during adolescence
in FXS is occurring at the same time that cognitive develop-
ment is actually slowing in FXS, a pattern not seen in non-
syndromic ASD.
4. Within-syndrome comparisons of individuals with FXS with
and without a diagnosis of autism have uncovered differ-
ences that are not always consistent with expectations for the
“essence” of ASD. On the one hand, individuals with FXS
and comorbid autism have more severe receptive language
problems than do their FXS peers without an autism diagnosis.
On the other hand, these two subgroups do not differ in terms
of the social impairments that represent the core deficit of
autism, once differences in IQ are controlled, although the data
are not consistent across studies in the regard. Replication is
thus required.
5. In terms of neurobiology, here too we see striking differ-
ences between FXS and nonsyndromic ASD in terms of brain
structure as well as some more subtle differences in terms
of brain function. At the same time, there are differences
and similarities in brain structure as regards the distinction
between individuals with FXS with and without comorbid
ASD. Finally, FMRP does not appear to map strongly onto
autism symptomatology in FXS.
Although these data strongly suggest that ASD is “not the same
disorder” in the FXS and non-syndromic ASD populations, sev-
eral caveats should be noted. First, in light of the clinical impor-
tance of a “mischaracterization” of the problem to be treated, the
data we have presented are limited in many ways. Larger, more
diverse, samples are needed to ensure that we understand the
limits of generalizability of our findings. Examination of these
issues across the entire life course is needed, and the samples
studied must be enriched in terms of representation of females.
Second, although the profile of relative impairments, relation-
ships among impairments, and trajectories of impairment differ
between individuals with FXS and comorbid ASD and individuals
with non-syndromic ASD, there is considerable overlap, and not
absolute difference. It is, however, premature to identify with
any certainty the individual symptoms that are reliably common
across the two disorders because of variations in sample character-
istics and measures across studies and because a lack of differences
between participant groups can often reflect limited statistical
power. Nevertheless, the available data suggest that many com-
munication impairments may be common across individuals with
FXS and comorbid ASD and individuals with non-syndromic
ASD (McDuffie et al., 2010, 2014; Losh et al., 2012), although
not necessarily only those symptoms seen as diagnostic of ASD.
Finally, the mechanisms, or psychological problems, underlying
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these differences between the two disorders are not fully explained
by the data thus far, although anxiety (Kaufmann et al., 2008;
Cordeiro et al., 2011), hyperactivity (Thurman et al., 2014), social
withdrawal (Budimirovic et al., 2006; Kaufmann et al., 2008), and
adaptive socialization (Budimirovic et al., 2006; Hernandez et al.,
2009) may play central roles in the emergence of ASD in FXS.
Ultimately, we believe that more studies of brain structure and
function, as well as the biological levels intervening between the
FMR1 gene and behavior, are needed to tie these differences at the
behavioral level to underlying pathology so that we can arrive at a
level of explanation that can guide treatment.
We also note that part of the “confusion” about the comorbid-
ity of FXS and ASD may be traced to reliance on the ADOS and
the ADI-R. These measures work very well, and are the gold stan-
dards, for diagnosing ASD in non-syndromic individuals, which
is the purpose for which they were designed. In the case of FXS
(and perhaps other syndromes); however, the range of options
for scoring might lead an impairment or unusual behavior to
be scored as “autistic” because that is simply a better fit than a
score reflecting unimpaired or typical. Perhaps a re-norming of
these measures for FXS or the use of a coding scheme that allows
finer distinctions to capture the difference between FXS and non-
syndromic ASD impairments is needed.
The most important implication of the findings considered
in this article is that the use of the categorical diagnosis of
ASD in FXS masks important differences within the syndrome
and between the syndrome and non-syndromic cases of ASD.
These differences that are masked by the diagnosis include both
individual symptoms that could be the targets of treatments and
the underlying mechanisms that can inform the nature of the
treatment required.
In conclusion, we still believe that the study of FXS can provide
insights into non-syndromic ASD. As Harris (2011) argued, and
our data support, those insights will come only when we abandon
reliance on the categorical ASD diagnosis, and we move to the
level of individual symptoms or constellations of symptoms that
truly reflect the same underlying mechanisms in FXS and non-
syndromic ASD. In the interim, it is naïve and counterproductive
to assume that ASD is the same in FXS as it is in the non-
syndromic case or that treatments will essentially “transfer” read-
ily from one condition to the other.
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